BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 17319470)

  • 1. Insulin glargine in the treatment of type 1 and type 2 diabetes.
    Barnett AH
    Vasc Health Risk Manag; 2006; 2(1):59-67. PubMed ID: 17319470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
    Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
    Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F; Carabino JM; Vergara CM
    Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.
    Raslova K
    Vasc Health Risk Manag; 2010 Jun; 6():399-410. PubMed ID: 20539842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
    Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
    Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin glargine: commentary on the duration of action and lower risk of nocturnal hypoglycaemia in patients with diabetes.
    Rosenstock J; Owens D
    Expert Opin Pharmacother; 2004 Jan; 5(1):1-2; author reply 2-3. PubMed ID: 14680430
    [No Abstract]   [Full Text] [Related]  

  • 7. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus.
    McKeage K; Goa KL
    Drugs; 2001; 61(11):1599-624. PubMed ID: 11577797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus.
    Chatterjee S; Tringham JR; Davies MJ
    Expert Opin Pharmacother; 2006 Jul; 7(10):1357-71. PubMed ID: 16805721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
    Bolli GB; Kerr D; Thomas R; Torlone E; Sola-Gazagnes A; Vitacolonna E; Selam JL; Home PD
    Diabetes Care; 2009 Jul; 32(7):1170-6. PubMed ID: 19389820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
    Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
    Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
    Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment.
    Lepore G; Dodesini AR; Nosari I; Trevisan R
    Diabetes Care; 2003 Apr; 26(4):1321-2. PubMed ID: 12663625
    [No Abstract]   [Full Text] [Related]  

  • 15. Glycemic variation and hypoglycemia in patients with well-controlled type 1 diabetes on a multiple daily insulin injection program with use of glargine and ultralente as basal insulin.
    Kudva YC; Basu A; Jenkins GD; Pons GM; Vogelsang DA; Rizza RA; Smith SA; Isley WL
    Endocr Pract; 2007; 13(3):244-50. PubMed ID: 17599855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
    Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
    Yki-Järvinen H; Dressler A; Ziemen M;
    Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treat-to-target trials: uses, interpretation and review of concepts.
    Garber AJ
    Diabetes Obes Metab; 2014 Mar; 16(3):193-205. PubMed ID: 23668598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes.
    Hamann A; Matthaei S; Rosak C; Silvestre L;
    Diabetes Care; 2003 Jun; 26(6):1738-44. PubMed ID: 12766103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
    Valensi P; Cosson E
    Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.